2016 - 2018

Categories:History
Author:
Origin:
Time of issue:2018-03-09
Views:0

(Summary description)
◆ Successfully obtaininginvestmentin SeriesPre-A round financing.
◆ Obtaining permissions forclinical trials of severalClass3.1 new drugs.
◆ Submitting applications for clinical study of a Class 1.1 new hypoglycemic drug.

2016 - 2018

(Summary description)
◆ Successfully obtaininginvestmentin SeriesPre-A round financing.
◆ Obtaining permissions forclinical trials of severalClass3.1 new drugs.
◆ Submitting applications for clinical study of a Class 1.1 new hypoglycemic drug.

Categories:History
Author:
Origin:
Time of issue:2018-03-09
Views:0

2016-2018

Previous: 2018 - 2019

Next: 2015 - 2016

Previous: 2018 - 2019

Next: 2015 - 2016

New Information | Series C financing of over 100 million yuan marks the first round of financing for Shengshi Taike, paving the way for commercialization of core innovative products

2024-09-04

Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, has been selected as a "Double Innovation Talent" in Jiangsu Province

Recently, the "Double Innovation Talent Plan" organized by the Jiangsu Provincial People's Government and the Provincial Talent Office was awarded a certificate of selection, and Dr. Wang Tong, Chief Scientific Officer of Shengshi Taike, was selected for the "2023 Jiangsu Province High level Innovation and Entrepreneurship Talent Introduction Plan". The Shengshi Taike R&D team led by Dr. Wang Tong is committed to the development of high-quality and differentiated small molecule innovative drugs, aiming to address major clinical pain points in the fields of blood sugar reduction, anti-tumor, and autoimmune diseases.

2024-07-31